ANDA 74912, held by Kenton. Selegiline Hydrochloride.
As of Nov 21, 2026, ANDA 74912 (Selegiline Hydrochloride), held by Kenton, was first approved by FDA on Apr 30, 1998, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 1998 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Selegiline Hydrochloride5MG · tablet;oral | Selegiline Hydrochloride | Discontinued |
| Dec 22, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Nov 17, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Nov 17, 2000 | Supplement 3Manufacturing | Approved | None posted |
| Apr 30, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters